$INTI
Inhibitor Therapeutics, Inc.

2020 Q3 Form 10-Q Financial Statement

#000119312520217120 Filed on August 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $270.3K $262.4K $331.9K
YoY Change -15.12% -20.95% -7.81%
% of Gross Profit
Research & Development $32.47K $52.66K $303.6K
YoY Change -91.09% -82.65% -42.6%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $302.8K $315.0K $635.5K
YoY Change -55.66% -50.43% -28.14%
Operating Profit -$302.8K -$315.0K -$635.5K
YoY Change -55.66% -50.43% -28.14%
Interest Expense $10.00 $150.00 $2.810K
YoY Change -99.77% -94.66%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$302.8K -$314.9K -$632.7K
YoY Change -55.38% -50.23% -28.1%
Income Tax
% Of Pretax Income
Net Earnings -$302.8K -$314.9K -$632.7K
YoY Change -55.38% -50.23% -28.26%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$811.40 -$850.00 -$1.708K
COMMON SHARES
Basic Shares Outstanding 373.6M 370.4M 370.4M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.71K $137.3K $2.025M
YoY Change -97.32% -93.22% 153.15%
Cash & Equivalents $36.71K $137.3K $2.025M
Short-Term Investments
Other Short-Term Assets $35.29K $40.03K $38.01K
YoY Change -30.34% 5.31% -86.89%
Inventory
Prepaid Expenses $35.29K $40.03K $38.01K
Receivables
Other Receivables
Total Short-Term Assets $72.00K $177.3K $2.063M
YoY Change -94.94% -91.4% 89.84%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $31.73K $39.05K $68.35K
YoY Change -48.0% -42.86% -30.0%
Total Long-Term Assets $31.73K $39.05K $68.35K
YoY Change -48.0% -42.86% -30.0%
TOTAL ASSETS
Total Short-Term Assets $72.00K $177.3K $2.063M
Total Long-Term Assets $31.73K $39.05K $68.35K
Total Assets $103.7K $216.4K $2.132M
YoY Change -93.01% -89.85% 79.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $251.5K $158.5K $195.3K
YoY Change -12.05% -18.86% -40.11%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $23.11K $16.18K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $458.5K $461.6K $304.8K
YoY Change 27.75% 51.45% -34.02%
LONG-TERM LIABILITIES
Long-Term Debt $18.49K $25.42K $0.00
YoY Change
Other Long-Term Liabilities $3.000M $3.000M $3.000M
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $3.018M $3.025M $3.000M
YoY Change 0.62% 0.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $458.5K $461.6K $304.8K
Total Long-Term Liabilities $3.018M $3.025M $3.000M
Total Liabilities $3.477M $3.487M $3.305M
YoY Change 3.52% 5.51% 615.49%
SHAREHOLDERS EQUITY
Retained Earnings -$57.07M -$56.71M -$54.50M
YoY Change 3.33% 4.06% 8.17%
Common Stock $49.73M $49.48M $49.36M
YoY Change 0.69% 0.24% 1.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.373M -$3.271M -$1.173M
YoY Change
Total Liabilities & Shareholders Equity $103.7K $216.4K $2.132M
YoY Change -93.01% -89.85% 79.96%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$302.8K -$314.9K -$632.7K
YoY Change -55.38% -50.23% -28.26%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$100.6K -$207.0K -$605.5K
YoY Change -81.83% -65.82% -23.35%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 41.60K 1.500M
YoY Change -100.0% -97.23% 14900.0%
NET CHANGE
Cash From Operating Activities -100.6K -207.0K -605.5K
Cash From Investing Activities
Cash From Financing Activities 0.000 41.60K 1.500M
Net Change In Cash -100.6K -165.4K 894.5K
YoY Change -84.59% -118.49% -214.68%
FREE CASH FLOW
Cash From Operating Activities -$100.6K -$207.0K -$605.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
39054
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53700
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137317
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
803816
CY2020Q2 us-gaap Assets
Assets
216400
CY2019Q4 us-gaap Assets
Assets
899966
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
40029
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
42450
CY2020Q2 us-gaap Assets Current
AssetsCurrent
177346
CY2019Q4 us-gaap Assets Current
AssetsCurrent
846266
CY2020Q2 us-gaap Liabilities
Liabilities
3487000
CY2019Q4 us-gaap Liabilities
Liabilities
3431101
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
158508
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
315940
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
86344
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14339
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
461578
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
431101
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
37045
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
37045
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
216400
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
899966
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49444525
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49384953
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56713036
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55913999
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-3270600
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
150116
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
500370
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
550370
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
926730
us-gaap Operating Expenses
OperatingExpenses
700486
us-gaap Operating Expenses
OperatingExpenses
1427100
us-gaap Operating Income Loss
OperatingIncomeLoss
-700486
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-2948596
CY2020Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2019Q1 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
99946
CY2019Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-786288
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-572275
CY2019Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-1173215
us-gaap Profit Loss
ProfitLoss
-699311
us-gaap Profit Loss
ProfitLoss
-1418979
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1175
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
8121
us-gaap Net Income Loss
NetIncomeLoss
-699311
us-gaap Net Income Loss
NetIncomeLoss
-1418979
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
315044
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
635500
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-315044
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-635500
us-gaap Operating Income Loss
OperatingIncomeLoss
-1427100
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370446185
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370418176
CY2020Q2 us-gaap Revenues
Revenues
0
CY2019Q2 us-gaap Revenues
Revenues
0
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52661
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
303596
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
262383
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
331904
CY2020Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
150
CY2019Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2809
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-314894
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-632691
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370446185
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370446185
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-2531135
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
16819
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
42753
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32351
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
131031
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370446185
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370446185
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370446185
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370446185
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
81614
CY2020Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
200548
CY2019Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
100822
CY2020Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
99726
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
99178
inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-799037
inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-1518157
CY2020Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49863
CY2019Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49863
CY2020Q2 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-364757
CY2019Q2 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-682554
CY2020Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-384417
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
373635873
us-gaap Share Based Compensation
ShareBasedCompensation
59572
us-gaap Share Based Compensation
ShareBasedCompensation
212645
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17067
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17935
inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
99178
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-85427
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-395114
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-708099
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1583513
inti Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
0
inti Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
2500000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41600
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2500000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-666499
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
916487
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1108713
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2025200
us-gaap Stock Issued1
StockIssued1
0
us-gaap Stock Issued1
StockIssued1
99946
inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
99726
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
inti Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q2 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
16178
CY2020Q2 us-gaap Notes Payable To Bank Noncurrent
NotesPayableToBankNoncurrent
25422
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
41600
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Estimates </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimat<div style="display:inline;">e</div>s. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001193125-20-217120-index-headers.html Edgar Link pending
0001193125-20-217120-index.html Edgar Link pending
0001193125-20-217120.txt Edgar Link pending
0001193125-20-217120-xbrl.zip Edgar Link pending
d914242d10q.htm Edgar Link pending
d914242dex311.htm Edgar Link pending
d914242dex312.htm Edgar Link pending
d914242dex321.htm Edgar Link pending
d914242dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
inti-20200630.xml Edgar Link completed
inti-20200630.xsd Edgar Link pending
inti-20200630_cal.xml Edgar Link unprocessable
inti-20200630_def.xml Edgar Link unprocessable
inti-20200630_lab.xml Edgar Link unprocessable
inti-20200630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending